Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference
The aforementioned data related to AK112-201 was generated and analyzed by Akeso.
- The aforementioned data related to AK112-201 was generated and analyzed by Akeso.
- Both studies represent ivonescimab in randomized, pivotal clinical trials against the standard of care in their respective settings.
- “As the data continues to mature in Phase II studies evaluating ivonescimab, including data related to the survival of patients impacted by these terrible diseases, our belief and conviction in ivonescimab is reinforced,” stated Summit’s Chief Executive Officers, Robert W. Duggan and Dr. Maky Zanganeh.
- We believe that the potential created by the differentiated mechanism of action and supporting trial data for ivonescimab deserves a swift development plan to bring ivonescimab to those patients who can benefit most.